Log in

NASDAQ:CANFCan-Fite Biopharma Stock Price, Forecast & News

+0.10 (+4.88 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $2.15
50-Day Range
MA: $1.85
52-Week Range
Now: $2.15
Volume463,413 shs
Average Volume952,553 shs
Market Capitalization$18.64 million
P/E RatioN/A
Dividend YieldN/A
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolNASDAQ:CANF



Sales & Book Value

Annual SalesN/A



Market Cap$18.64 million
Next Earnings Date6/3/2020 (Estimated)

Receive CANF News and Ratings via Email

Sign-up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter.

Can-Fite Biopharma (NASDAQ:CANF) Frequently Asked Questions

How has Can-Fite Biopharma's stock been impacted by COVID-19 (Coronavirus)?

Can-Fite Biopharma's stock was trading at $1.52 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CANF stock has increased by 41.4% and is now trading at $2.15. View which stocks have been most impacted by Coronavirus.

When is Can-Fite Biopharma's next earnings date?

Can-Fite Biopharma is scheduled to release its next quarterly earnings announcement on Wednesday, June 3rd 2020. View our earnings forecast for Can-Fite Biopharma.

How were Can-Fite Biopharma's earnings last quarter?

Can-Fite Biopharma Ltd (NASDAQ:CANF) announced its quarterly earnings results on Friday, March, 27th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.29. The firm earned $0.19 million during the quarter. View Can-Fite Biopharma's earnings history.

Has Can-Fite Biopharma been receiving favorable news coverage?

Media headlines about CANF stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Can-Fite Biopharma earned a coverage optimism score of 2.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutCan-Fite Biopharma.

Who are some of Can-Fite Biopharma's key competitors?

What other stocks do shareholders of Can-Fite Biopharma own?

Who are Can-Fite Biopharma's key executives?

Can-Fite Biopharma's management team includes the following people:
  • Prof. Pnina Fishman Ph.D., Scientific Founder, Chief Exec. Officer & Director (Age 70)
  • Mr. Motti Farbstein, Chief Operating & Financial Officer (Age 54)
  • Dr. Ilan Cohn Ph.D., Co-Founder & Chairman (Age 64)
  • Dr. Michael H. Silverman M.D., F.A.C.P.,FACR, Medical Director
  • Dr. Vibeke Strand M.D., FACP, FACR (USA), Sr. Clinical Advisor

What is Can-Fite Biopharma's stock symbol?

Can-Fite Biopharma trades on the NASDAQ under the ticker symbol "CANF."

How do I buy shares of Can-Fite Biopharma?

Shares of CANF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Can-Fite Biopharma's stock price today?

One share of CANF stock can currently be purchased for approximately $2.15.

How big of a company is Can-Fite Biopharma?

Can-Fite Biopharma has a market capitalization of $18.64 million.

What is Can-Fite Biopharma's official website?

The official website for Can-Fite Biopharma is www.canfite.co.il.

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.